Alluvi, known as BI 4744, represents a significant development in obesity care. This dual agonist targeting both glucagon-like peptide-1 and GIP targets demonstrates remarkable efficacy in patient trials, arguably https://alluvi-peptides499848.sunderwiki.com/user